Payment overview · 2025
General Payments
$1,081.77
59 reported records · 14 companies
Healthcare provider profile · identity verified
James L Patterson, DO
Allopathic & Osteopathic Physicians|Family Medicine · BUTLER, MO · NPI 1871579706
Verified facts
What the public records show
CMS Open Payments records show James L Patterson, DO received $1,081.77 in general payments during 2025 across 59 reported records.
ABBVIE INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $355.81 | 32.9% | 28 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $316.23 | 29.2% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $110.23 | 10.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.06 | 6.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.14 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.85 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.63 | 2.9% | 2 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $23.91 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.65 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.23 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.28 | 1.7% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $15.39 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.99 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.37 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,081.77 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $276.03 | 24 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.30 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $110.23 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $107.20 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.92 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.78 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.78 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.01 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
100 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 121 |
| Gabapentin | Gabapentin | 591 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 127 |
| Alprazolam | Alprazolam | 469 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 385 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 364 | 74 |
| Furosemide | Furosemide | 338 | 88 |
| Metformin Hcl | Metformin Hcl | 304 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 299 | 70 |
| Potassium Chloride | Potassium Chloride | 289 | 56 |
| Lisinopril | Lisinopril | 272 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 233 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 50 |
| Omeprazole | Omeprazole | 223 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 70 |
| Losartan Potassium | Losartan Potassium | 204 | 44 |
| Tramadol Hcl | Tramadol Hcl | 196 | 45 |
| Simvastatin | Simvastatin | 187 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 50 |
| Telmisartan | Telmisartan | 171 | 37 |
| Eliquis | Apixaban | 167 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 161 | 35 |
| Meloxicam | Meloxicam | 152 | 29 |
| Alendronate Sodium | Alendronate Sodium | 142 | 36 |
| Aripiprazole | Aripiprazole | 142 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 130 | 85 |
| Trazodone Hcl | Trazodone Hcl | 123 | 26 |
| Prednisone | Prednisone | 122 | 75 |
| Allopurinol | Allopurinol | 120 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 120 | 19 |
| Warfarin Sodium | Warfarin Sodium | 119 | 14 |
| Sertraline Hcl | Sertraline Hcl | 110 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 19 |
| Levofloxacin | Levofloxacin | 108 | 78 |
| Paroxetine Hcl | Paroxetine Hcl | 107 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 26 |
| Azithromycin | Azithromycin | 104 | 74 |
| Carvedilol | Carvedilol | 103 | 22 |
| Montelukast Sodium | Montelukast Sodium | 101 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 20 |
| Vraylar | Cariprazine Hcl | 100 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 24 |
| Spironolactone | Spironolactone | 95 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 93 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 91 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 18 |
| Topiramate | Topiramate | 88 | 20 |
| Pregabalin | Pregabalin | 85 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 19 |
| Glipizide | Glipizide | 82 | 18 |
| Clonazepam | Clonazepam | 80 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 21 |
| Finasteride | Finasteride | 71 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 15 |
| Baclofen | Baclofen | 70 | 11 |
| Mirtazapine | Mirtazapine | 69 | 17 |
| Fentanyl | Fentanyl | 66 | suppressed |
| Eszopiclone | Eszopiclone | 65 | 13 |
| Famotidine | Famotidine | 65 | 12 |
| Farxiga | Dapagliflozin Propanediol | 65 | 15 |
| Glimepiride | Glimepiride | 62 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 47 |
| Celecoxib | Celecoxib | 61 | 11 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Ondansetron Odt | Ondansetron | 60 | 22 |
| Varenicline Tartrate | Varenicline Tartrate | 58 | 21 |
| Torsemide | Torsemide | 57 | 14 |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 19 |
| Donepezil Hcl | Donepezil Hcl | 52 | 12 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Lorazepam | Lorazepam | 51 | 13 |
| Metformin Hcl Er | Metformin Hcl | 51 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Rexulti | Brexpiprazole | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Clonidine | Clonidine | 46 | suppressed |
| Sucralfate | Sucralfate | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 12 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 22 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Brilinta | Ticagrelor | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Fluconazole | Fluconazole | 31 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 17 |
| Temazepam | Temazepam | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Nystatin | Nystatin | 27 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 13 |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Icatibant | Icatibant Acetate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Leflunomide | Leflunomide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,081.77 · 59 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, FANAPT, FARXIGA, FREESTYLE LIBRE, MOUNJARO, ORLADEYO, OTEZLA, QULIPTA, REPATHA, REXULTI, SMARTVEST, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error